FINWIRES · TerminalLIVE
FINWIRES

NSE:SUNPHARMA

5 stories mentioning NSE:SUNPHARMA

Every FINWIRES story that references NSE:SUNPHARMA, newest first.

Asia

Indian Equities End Higher on Friday as Banking Stocks Lift Sentiment

Indian benchmark indices closed higher on Friday, supported by gains in heavyweight banking stocks.The BSE Sensex rose 231.99 points, or 0.3%, to close at 75,415.35, while the NSE Nifty 50 gained 64.60 points, or also 0.3%, to settle at 23,719.30.Investor sentiment remained mixed as Brent crude oil prices climbed more than 2% to trade above $105 per barrel amid continued uncertainty over a potential U.S.-Iran agreement.Meanwhile, the Indian rupee extended its recovery against the U.S. dollar, strengthening to 95.7 after touching a record low of 96.96 earlier in the month. Market participants continued to track intervention measures by the Reserve Bank of India aimed at stabilizing the currency.In earnings news, Minda Corp. (NSE:MINDACORP, BOM:538962) surged nearly 8% after fiscal fourth-quarter consolidated profit rose sharply to 1.25 billion rupees from 520.3 million rupees a year earlier.Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) declined over 2% despite reporting a higher fiscal fourth-quarter consolidated net profit of 27.1 billion rupees, compared with 21.5 billion rupees a year ago.Suzlon Energy (NSE:SUZLON, BOM:532667) gained nearly 2% after receiving a repeat 195 MW order from Sunsure Energy for a project in Karnataka, the company said in an exchange filing on Friday.

^BSENifty 50BOM:524715BOM:532667BOM:538962NSE:MINDACORPNSE:SUNPHARMANSE:SUZLON
Asia

Sun Pharmaceutical Industries Consolidated Profit Grows in Fiscal Q4; Shares Slip 3

Sun Pharmaceutical Industries' (NSE:SUNPHARMA, BOM:524715) consolidated net profit increased to 27.1 billion Indian rupees in the fiscal fourth quarter ended March 31, from 21.5 billion rupees a year ago.Earnings per share climbed to 11.3 rupees from the year-ago figure of 9.0 rupees, according to a Friday filing to the Indian stock exchanges by the pharmaceutical company.Total revenue from operations in fiscal Q4 jumped to 146.1 billion rupees from 129.6 billion rupees a year earlier.The company's board declared a final dividend of 5 rupees per share for the financial year ended March 31.Sun Pharma's shares were down nearly 3% in recent trade.

BOM:524715NSE:SUNPHARMA
Asia

Indian Equities Rebound on Monday as Value Buying, US-Iran Talk Hopes Lift Market

Indian benchmark indices closed higher on Monday, snapping a three-day losing streak, as value buying and expectations of renewed U.S.-Iran talks supported the market.The BSE Sensex rose 639.42 points, or 0.8%, to close at 77,303.63, while the NSE Nifty 50 gained 194.75 points, or also 0.8%, to settle at 24,092.70.Sentiment improved on expectations that the US and Iran may resume talks soon. Stronger-than-expected quarterly earnings also helped boost investor confidence.Among stocks, Tamilnad Mercantile Bank (NSE:TMB, BOM:543596) gained 7% after reporting a rise in fiscal Q4 net profit to 3.74 billion rupees from 2.92 billion rupees a year earlier. Earnings per share increased to 23.60, while interest income rose to 15.5 billion rupees.Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) also jumped 7% after agreeing to acquire US-based Organon & Co in an all-cash deal valued at $11.8 billion. The company will purchase shares at $14 each and plans to fund the transaction through cash and bank financing.

^BSENifty 50BOM:524715BOM:543596NSE:SUNPHARMANSE:TMB
Asia

Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal

Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.

BOM:524715NSE:SUNPHARMA
Asia

Sun Pharmaceutical Industries Forms New Wholly-Owned Subsidiary in US; Shares Down 4%

Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has incorporated a new wholly-owned subsidiary company in the US named "Sun Pharma America, Inc." according to a Friday filing to the Indian stock exchanges.The new subsidiary has been formed as part of the company's internal group structuring.The company's shares were down nearly 4% n recent trade.

BOM:524715NSE:SUNPHARMA